Advanced Oncotherapy (AVO)

Sector:

Health Care

 1.93p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 25.00
  • 52 Week Low: 1.75
  • Currency: UK Pounds
  • Shares Issued: 542.57m
  • Volume: 0
  • Market Cap: £10.44m

Regulatory News

Further update on financing discussions 02-Apr-2024 15:50 RNS
Further update on financing discussions 29-Feb-2024 17:19 RNS
Further update on financing discussions 01-Feb-2024 07:00 RNS
Update on Financing Discussions 09-Jan-2024 09:00 RNS
Update on Financing and Current Financial Position 23-Oct-2023 07:00 RNS
Recapitalisation and funding plan, update on FSP 17-Jul-2023 07:00 RNS
Total Voting Rights 30-Jun-2023 17:00 RNS
Suspension - Advanced Oncotherapy PLC 30-Jun-2023 07:30 RNS
Update on financing, suspension of trading on AIM 30-Jun-2023 07:15 RNS
Holding(s) in Company 29-Jun-2023 13:35 RNS
Form 8.3 - Advanced Oncotherapy PLC 29-Jun-2023 09:59 RNS
Form 8.3 - Advanced Oncotherapy PLC 28-Jun-2023 10:25 RNS
Form 8.3 - Advanced Oncotherapy 27-Jun-2023 10:29 RNS
Form 8.3 - Advanced Oncotherapy 27-Jun-2023 10:25 RNS
Form 8.3 - Advanced Oncotherapy 26-Jun-2023 16:26 RNS
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

AVO Market Data

Currency UK Pounds
Share Price 1.93p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 25.00
52 Week Low 1.75
Volume 0
Shares Issued 542.57m
Market Cap £10.44m

AVO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
71.33% below the market average71.33% below the market average71.33% below the market average71.33% below the market average71.33% below the market average
40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average
Income Not Available
Growth Not Available

AVO Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

AVO Key Personnel

CEO Nicolas Serandour

Top of Page